Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MorphoSys AG Investor Presentation 2009

Apr 30, 2009

291_ip_2009-04-30_0a426694-1c36-4b91-b7fa-948c59482bb9.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Company Update

April 2009

Safe Harbour

This presentation includes forward forward-looking statements. looking

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic comp ,g y , g g etitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

Morp y hoS s at a Glance

C
o
m
p
a
n
y		 A
i
d
d
i
b
d
t
t
"
n
n
e
p
e
n
e
n
a
n
o
c
o
m
p
a
n
y
y
B
d
i
i
l
i
i
h
d
&
t
t
t
t
t
"
r
o
a
a
r
a
c
e
p
p
e
n
e
p
a
r
n
e
r
e
n
v
w
u
-
,
t
d
i
i
i
d
i
t
i
p
a
r
n
e
r
e
p
r
o
g
r
a
m
s
n
v
a
r
o
u
s
n
c
a
o
n
s
T
h
i
&
h
i
b
d
t
t
t
"
e
r
a
p
e
u
c
r
e
s
e
a
r
c
a
n
o
y
s
e
g
m
e
n
s
O
i
i
t
r
g
a
n
a
o
n
z		 H
Q
M
i
i
d
(
M
i
h
)
/
D
b
i
d
i
i
i
t
"
a
r
n
s
r
e
n
c
s
s
a
r
e
s
n
u
u
,
D
D
ü
ü
l
l
d
d
f
f
/
/
D
D
O
f
d
/
U
K
&
R
l
i
h
/
U
S
A
s
s
s
s
e
e
o
o
r
r
o
r
a
e
g
x
,
3
4
3
l
l
d
i
d
"
e
m
p
o
y
e
e
s
w
o
r
w
e
L
i
d
t
s
e		 F
k
f
S
k
E
E
h
h
T
D
A
X
t
t
"
r
a
n
r
o
c
c
c
a
a
n
n
g
g
e
e
e
c
u
x
x
,
1
A
D
R
L
l
"
e
v
e
T
h
l
e
c
n
o
o
g
y		 C
C
f
f
L
L
d
d
i
i
i
i
H
H
A
A
L
L
l
l
t
t
t
t
"
e
a
n
g
p
r
o
p
r
e
a
r
y
u
p
a
o
r
m
,
S
&
d
i
d
t
t
t
t
t
t
"
r
o
n
g
n
s
p
e
p
a
e
n
e
s
a
e
u
u
F
i
i
l
n
a
n
c
a
s		 P
P
f
f
i
i
b
b
l
l
b
l
h
t
t
t
t
"
r
r
o
o
a
a
e
e
s
r
o
n
g
a
a
n
c
e
s
e
e
,

Financial Strength in the Downturn

  • Strong balance sheet with > € 130 million in cash
  • Operational cash flow in 2008 of approximately € 29 million
  • Secure revenues 2009 – 2017 in amount of > € 400 million
  • Milestone & royalty potential >> € 1 billion

HuCAL stands for Human Combinatorial Antibody Library

Modular gene design & construction

  • Antibodies are fully human
  • Modular gene construction enables systematic optimization of antibody lead candidates f h th ti li ti for eactherapeutic application
  • Proprietary phage-based CysDisplay screening system
  • Proprietary AutoCAL system for high throughput
  • HuCAL PLATINUM launched in December 2008

HuCAL PLATINUMBrighter than GOLD

G
O
L
D		 P
L
A
T
I
N
U
M
L
i
b
i
r
a
r
y
s
z
e		 1
2
M
d
r		 4
5
M
d
r
U
d
l
i
d
b
t
n
e
r
n
g
a
a
a
s
e
y		 1
9
9
7		 2
0
0
8
f
f
D
D
i
i
i
i
t
t
i
i
l
l
t
t
d
d
t
t
i
i
b
b
d
d
i
i
v
e
r
s
y
o
s
o
a
e
a
n
o
e
s		 1
x		 2
5
x
A
f
f
i
i
i
t
n
e
s		 1
x		 4
x
P
d
i
t
r
o
c
o
n
u		 1
x		 3
x

HUCAL - Commercial Success Story

  • More than 50 active therapeutic programs
  • More than 1,000 custom research antibody projects concluded
  • HuCAL GOLD has generated more than € 200 million in revenues in the form of license and success-based payments and research services
  • Royalties on HuCAL GOLD-based products still to come

Robust Intellectual Propy y ert y Protected b Core Patent Families

  • HuCAL Library Design and Use (~2016 expiry)
  • 5 US Patents
  • 2 EP Patents (several EU states)
  • 2 AU Patents
  • Pending applications: CA EP JP US
  • TRInucleotide Mutagenesis (JHU excl. license) (~2013 expiry)
  • 1 US Patent; 1 EP and 1 JP patent; pending in CA
  • Di lfid Di l ( Disulfide Display (C Di l ys sp ay) ( 2020 i ) ) (~2020 expiry)
  • 1 US and 1 EP Patent
  • Pending applications: AU CA EP IL JP NO US
  • Technology Development (HuCAL PLATINUM®)
  • Several applications pending
  • Co-exclusive access to various Dyax biologics patent families
  • Patent applications for antibody drug candidates
  • Patent filings and inlicensed patents for proprietary candidates

Business Segments

Value Througg p h Strong Partnerships

2
0
0
7		 2
0
0
8		 2
0
0
9		 2
0
1
0		 2
0
1
1		 2
0
1
2
N
i
t
o
v
a
r
s
A
l
l
t
s
e
a
s
P
f
i
e
r
z
S
h
i
i
o
n
o
g
S
h
i
P
l
h
c
e
r
n
g
o
u
g
-
D
i
i
h
i
S
k
a
c
a
n
y
o
&
C
M
k
e
r
c
o
B
h
i
I
l
h
i
o
e
r
n
g
e
r
n
g
e
e
m
O
d
n
c
o
m
e		 C
i
d
t
t
t
o
m
m
e
e
r
m
E
l
i
L
i
l
l
y		 O
t
i
l
p
o
n
a
R
h
o
c
e		 E
t
i
2
0
0
8
x
e
n
s
o
n
s
B
S
S
h
h
i
i
a
e
r
c
e
r
n
g
y
C
t
e
n
o
c
o
r		 O
i
n
g
o
n		 i
b
d
t
g
a
n
o
p
y		 r
o
g
r
a
m
s
P
h
r
o
c
o
n

¾58 active partnered therapeutic antibody programs

¾ E t d d t hi i 2008 id ti f th 15 dditi l Extended partnerships in 2008 provide options for more than 15 additional programs

Current Product Pipeline: 62 Programs Ongoing

N
a
m
e		 P
t
a
r
n
e
r		 i
i
I
d
t
n
c
a
o
n		 i
D
s
c
o
e
r
v
y		 i
i
P
l
r
e
c
n
c		 P
h
1
a
s
e		 P
h
a
s
e		 2
P
h
3
a
s
e		 M
k
t
a
r
e
G
t
b
a
n
e
n
e
r
u
m
a
(
)
R
1
4
5
0		 R
h
o
c
e		 's
A
l
h
i
z
e
m
e
r
D
i
s
e
a
s
e
Q
B
H
8
8
0		 N
t
i
o
v
a
r
s		 C
a
n
c
e
r
d.
n.		 C
t
e
n
o
c
o
r		 /
I
l
m
m
u
n
o
o
g
y
C
a
n
c
e
r		 5
P
8
t
a
r
n
e
r
e		 d
P
r
o
g
r
a
m
s
3
1
P
t
d
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
u
s		 *
V
i
a
r
o
u
s
2
3
P
t
d
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
u
s		 *
V
i
a
r
o
u
s
M
O
R
1
0
3		 - R
h
t
i
d
e
m
a
o
u
A
t
h
i
t
i
r
r
s
M
O
R
2
0
2		 - C
a
n
c
e
r		 3
P
i
t
r
o
p
r
e
a		 P
r
y
r
o
g
r
a
m
s
M
O
R
2
0
3		 - C
a
n
c
e
r
d.
n.		 M
h
S
/
o
r
p
o
s
y
N
i
t
o
a
r
s
v		 d.
n.		 1
P
D
r
e-
e
v.		 P
r
o
g
r
a
m

* Includes cancer, inflammatory, autoimmune, infectious, musculoskeletal & central nervous system diseases

Partnered Therap g eutic Programs: Structure

Partnership yp p g s: Typical Terms per Program

Partnered HuCAL Antibodies in Clinic1. Roche's Alzheimer Program

  • Gantenerumab (R1450)
  • HuCAL I g y G1 antibod
  • Targeting amyloidβ
  • Binds to Aβ peptides
  • Dep y ol ymerizes agg g re gated Aβ
  • Crosses blood-brain barrier in transgenic mouse, decreasing cerebral Aβ burden
  • Two Phase 1 studies
  • Single dose arm completed
  • Multi p g gg le ascendin g dose arm no lon ger recruitin g
  • Mild-to-moderate Alzheimer's patients
  • Randomized, double-blind
  • Antibody p behaves as ex pected

Partnered HuCAL Antibodies in Clinic2. Novartis's Cancer Program

BHQ880

  • HuCAL IgG1 antibody
  • Targeting DKK-1
  • Overexpression of DKK-1 by myeloma cells may upset the normal balance b t e ween ost bl t eo as s an d ost lt eocasts
  • DKK-1 may play a role in preventing osteolytic bone disease in multiple myeloma patients
  • Phase 1 study is ongoing in the US
  • P li i l t di t th h th i Precli nical studies support the hypothesis that BHQ880 promotes bone formation and thereby inhibits tumor-induced osteolytic disease
  • A phase 1/2 combination study in combination with Zometa/Reclast in relapsed or refractory myeloma patients h t t d i F b 2009has starte in ebruary

Partnered HuCAL Antibodies in Clinic3. Centocor's Cancer & Inflammation Program

  • HuCAL-derived fully human antibody in the therapeutic area of oncology
  • Phase 1 trial in oncology was started in June 2007, is ongoing
  • In November 2008, a phase 2 study in an additional indication (immunology) was started
  • IND filing for phase 2 study triggered a milestone payment to MorphoSys

Partnered Business: Projected HuCAL Drugs on the Market

Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development

Pip gy eline: Strategy

Propy p rietary Product Pipeline: Four Programs Ongoing

N
a
m
e		 P
t
a
r
n
e
r		 I
d
i
i
t
n
c
a
o
n		 D
i
s
c
o
v
e
r
y		 P
l
i
i
r
e
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
M
O
R
1
0
3		 - R
h
t
i
d
e
u
m
a
o
A
t
h
i
t
i
r
r
s
O
2
0
2
M
R		 - C
a
n
c
e
r		 3
P
i
t
r
o
p
r
e
a
r
y		 P
r
o
g
r
a
m
s
O
2
0
3
M
R		 - C
a
n
c
e
r
d.
n.		 M
h
S
/
o
r
p
o
y
s
N
i
t
o
a
r
s
v		 d.
n.		 P
D
P
1
r
e-
e
v.		 r
o
g
r
a
m
  • 4 proprietary programs are currently ongoing, another target was already selected
  • Focus on inflammation & cancer
  • Target sources: Dedicated target scouts, codevelopment (e.g. Galapagos) & in-licensing
  • Rigorous target selection process target
  • Detailed scientific evaluation (e.g. target biology)
  • Medical need, therapeutic potential, developability, etc.
  • IP: FTO and patentability

  • Commercial: Market potential and competition

  • MOR103, a fully human HuCAL antibody targeting GM-CSF

  • GM-CSF plays a central role in inflammation and auto CSF auto-immunity immunity
  • MOR103 blocks binding of GM-CSF to its receptor with pM affinity
  • Primary indication: Rheumatoid arthritis
  • Commercial opportunity: Anti-TNF therapies Enbrel, Remicade, Humira are successful biologic products for treating RA, but still under 25% of RA patients are adequately treated
  • Promising scientific and preclinical data
  • Successful completion of phase 1 in healthy volunteers (favorable safety profile after 5 cohorts led to trial trial-extension; in total 7 cohorts extension; total, with 9 volunteers each, were treated)
  • Data support development of GM-CSF mAb therapy in different inflammatory diseases (rheumatoid arthritis multiple sclerosis) and arthritis, and lung diseases (COPD, asthma)

MOR103IP and Outlook 2009

Patent applications covering key features of the MOR103

Outlook 2009:

ANTIBODY

Final results from phase 1 in healthy volunteers in Q2/2009

Broad patent protection for MOR103 in the US, the largest RA market:

program Exclusive License

WO 2006122797

  • Start of phase 1b/2a study in RA patients in H2 2009
  • Decision on second indication, based on efficacy in disease models in 2009

U.S. 7,455,836

key uses of

GM-CSF

antibodies against

MOR202Proprietary Cancer Program

  • MOR202, a fully human HuCAL antibody, targeting CD38, a 45 kDa ectoenzyme heavily over-expressed in 95% of MM celllines and some leukemia lines
  • Function: Induces cell-killing by ADCC, CDC & apoptosis
  • Primary indication: Multiple myeloma (MM) indication: (MM)
  • Commercial opportunity
  • 10 % of hematological cancers / 1% of all cancers / 2% of cancer deaths
  • No curative therapies
  • Median survival 24 – 30 months, all patients eventually relapse

Outlook 2009:

  • Further evaluation in animal models of multiple myeloma
  • Start of non non-clinical safety study to support clinical testing clinical
  • Start of preclinical efficacy studies in second indication
  • Production and release of mAb material for animal safety testing and in preparation for phase 1/2a clinical testing in 2010

Additional Prop y rietaryActivities

Novartis

  • Nomination of first pre-development program
  • Novartis funds joint efforts until the program reachf lesormal pre-cli i l d l t linical development
  • Option for MorphoSys to enter a formal co-development up to 50%

Galapagos

  • Access Galapagos's proven target discovery capabilities and disease know-how
  • Access novel antibody g tar ets in bone & joint disease with a high unmet medical need
  • Complement MOR's development efforts in inflammation and arthritis

Propy p rietary Product Pipeline: Projected Status Year-End 2009

N
a
m
e		 P
t
a
r
n
e
r		 I
d
i
i
t
n
c
a
o
n		 D
i
s
c
o
v
e
r
y		 P
l
i
i
r
e
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
R
h
t
i
d
e
u
m
a
o
A
h
i
i
t
t
r
r
s
O
1
0
3
M
R		 - R
i
t
e
s
p
r
a
o
r
y
S
M
M
O
R
2
0
2		 - C
a
n
c
e
r
M
O
R
2
0
3		 - C
a
n
c
e
r		 U
t
7
p
o		 P
i
t
r
o
p
r
e
a
r
y
O
M
R
2
0
5		 - C
a
n
c
e
r		 P
r
o
g
r
a
m		 s
O
M
R
x
x
x		 - d.
n.
O
M
R
x
x
x		 - d.
n.
M
O
R
x
x
x		 - d.
n.
d.
n.		 S
/
M
h
o
r
p
o
y
s
N
t
i
o
v
a
r
s		 d.
n.		 P
D
1
r
e-
e		 P
r
o
g
r
a
m
v.

Establish a rich proprietary pipeline based on proven HuCAL technology proprietary based HuCAL technology

Number of Partnered and Proprietary Clinical Compounds at Year-End 9

Clinical Antibody Pipeline is Future Value Driver is Future

Business Segments

AbD SerotecBusiness and Outlook

AbD SerotecHighlights & Challenges

  • First HuCAL antibody now marketed in diagnostics kit by partner Phadia
  • C ti ith th 20e.g. NIH Cooperation with more than diagnostics customers
  • Introduction of more than 5,000 new , products to catalog
  • Appointment of Dieter Feger from Abbott Diagnostics to head the unit

Highlights Challenges

  • Profitable General market slowdown for research antibodies
  • Research funding doesn't grow,
  • Weak USD and GBP compared to Euro
  • Write-down on UK property (Poole Real p p y( Estate)

FinancialsProfit & Loss Statement (Group)

FinancialsCondensed Balance Sheets (Group)

M
o
r
p		 h
S
G
o
y
s
r
o
u
p		 A b
D
S
t
e
g
m
e
n
I
I
E
E
U
U
R
R
i
i
l
l
l
l
i
i
n
m
o
n
s		 2
0
0
9
E
*		 2
0
0
8
A		 I
E
U
R
i
l
l
i
n
m
o
n
s		 2
0
0
9
E
*		 2
0
0
8
A
T
l
G
t
o
a
r
o
u
p
R
e
v
e
n
u
e
s		 8
0
8
5
–		 7
1
6		 A
b
D		 2
0
~		 1
8
2
G
O
i
t
r
o
u
p
p
e
r
a
n
g
f
i
P
t
r
o		 8
1
1
–		 1
6
4		 i
A
b
D
O
t
p
e
r
a
n
g
P
f
i
M
i
t
r
o
a
r
g
n		 2
%
i
i
T
l
R
&
D
t
t
t
t
o
a
p
r
o
p
r
e
a
r
n
e
s
m
e
n
y
v		 S
M
h
G
o
r
p
o
s
r
o
p
y
u
i
i
E
U
R
1
8
2
0
l
l
m
o
n
–
M
O
R
1
0
3
/
M
O
R
2
0
2
D
i
s
c
o
v
e
r
y
p
r
o
g
r
a
m
s		 S
b
"
c
c
e
s
s
a
s
u
-
i
l
t
a
p
p
p
p
r
o
m
a
e
x
P
i
R
t
"
r
o
p
r
e
a
r
y
1
8
E
U
R
t
E
U
o
O
l
k
t
o
o
u
f
A
i
i
1
0
"
m
n
g
o
r
t
h
g
r
o
w
f
M
i
t
i
"
a
n
a
n
p
r
o
i
l
i
p
p
e
n
e		 d
t
e
p
a
m
e
n
s
y
w
E
U
R
1
0
i
l
l
i
m
o
y
y
&
D
d
i
l
l
s
p
e
n
w
2
0
R
i
l
l
i
m
o
n
%
%
2
0
a
n
n
u
a
–
i
t
b
i
l
i
t
h
i
l
a
y
w
e
s
,
*
Es
t
im		 i
l
l
t
t
a
m
o
n
o
u
n
d
b
l
t
o
e
o
u
l
r
e
v
e
n
u
e
t
t
h
i
r
e
n
g
e
n
n
g
te
d
b
a
nu
m
e
rs

Shareholder Structure

C
t
o
r
p
o
r
a
e		 R
f
€
8
0
i
l
l
i
€
8
5
i
l
l
i
e
v
e
n
u
e
s
o
m
o
n
m
o
n
•
–
O
f
f
€
€
t
i
i
t
8
i
l
l
i
1
1
i
l
l
i
p
e
r
a
n
g
p
r
o
o
m
o
n
m
o
n
•
–
P
d
t
a
r
n
e
r
e
D
i
s
c
o
e
r
v
y		 2
4
I
N
D
s
•
–
2
0
t
t
n
e
p
r
o
g
r
a
m
s
a
r
s
w
•
P
i
R
&
D
t
r
o
p
r
e
a
r
y		 M
O
R
1
0
3
P
h
1
d
&
f
h
2
R
A
i
l
t
t
t
t
a
s
e
a
a
s
a
r
o
p
a
s
e
r
a
:
•
U
i
&
i
f
l
i
t
5
t
p
o
n
e
p
r
o
g
r
a
m
s
n
c
a
n
c
e
r
n
a
m
m
a
o
n
w
•
A
b
D		 R
f
€
2
0
i
l
l
i
e
e
n
e
s
o
a
p
p
r
o
m
o
n
v
u
x
•
f
P
i
t
i
t
l
t
2
0
0
8
l
l
r
o
m
a
r
g
n
a
e
a
s
o
n
e
v
e
•

Future Value Creation

Appendix

R
t
e
e
n
e
o
v
u
S
M
h
o
r
p
o
s
y		 L
d
k
d
l,
i
i
"
a
n
m
a
r
e
a
c
o
m
p
r
s
n
g
€
4
4
0
0
0
0
i
d
f
d
i
(
b
l
)
t
t
m
m
c
o
m
m
e
n
n
g
s
e
e
e
o
ƒ
u
w
€
2
0
i
i
l
(
b
b
i
l
i
i
h
d
)
5
t
t
t
t
>
ƒ
m
n
m
e
s
o
n
e
s
p
r
o
a
y
-w
e
g
e
a
s
s
e
s
s
m
e
n
D
t
i
l
d
l
t
i
ƒ
o
e
s
n
o
n
c
u
e
r
o
y
a
e
s
N
d
d
i
i
l
i
i
i
b
d
%
t
t
t
t
t,
t
t
7
o
a
o
n
a
e
q
n
n
e
e
s
s
m
m
e
e
n
n
e
o
n
c
r
r
e
n
ƒ
u
y
v
v
y
u
C
i
d
t
t
o
m
m
e
F
d
i
u
n
n
g		 €
A
4
0
0
1
0
"
p
p
r
o
x
m
o
v
e
r
y
e
a
r
s
A
h
l
f
(
€
2
0
0
)
i
h
l
l
i
f
l
i
l
i
i
f
f
t
t
t
p
p
r
o
a
m
n
e
c
n
o
o
g
c
e
n
s
e
e
e
s
p
s
n
e
r
n
a
a
o
n
e
e
o
r
ƒ
x
y
u
z
H
C
A
L
i
i
i
d
b
l
d
i
i
t
t
t
t
u
c
o
m
p
r
s
n
g
c
o
n
n
g
e
n
o
u
e
g
s
u
c
c
e
s
s
p
a
y
m
e
n
,
f
(
€
)
f
f
S
A
h
l
2
0
0
i
h
d
i
t
t
M
h
ƒ
p
p
r
o
x
a
m
n
r
e
s
e
a
r
c
u
n
n
g
o
r
e
a
m
a
o
r
p
o
y
s
T
e
r
m		 1
0
i
t
h
N
N
t
t
i
i
h
i
t
i
t
"
y
y
e
e
a
a
r
r
s
s
w
o
o
v
v
a
a
r
r
s
s
a
v
n
g
o
p
o
n
s
o
:
,
E
d
1
2
t
t
x
e
n
o
y
e
a
r
s
ƒ
T
i
f
i
f
i
h
l
l
t
t
7
t
t
t
t
e
r
m
n
a
e
a
e
r
e
a
r
s
c
e
r
a
n
e
c
n
o
o
g
g
o
a
s
a
r
e
n
o
m
e
ƒ
y
y
M
i
l
&
t
e
s
o
n
e
s
R
l
i
t
o
a
e
s
y		 O
l
l
"
n
a
p
r
o
g
r
a
m
s
C
C
d
d
l
l
t
o
e
v
e
o
p
m
e
n
-		 S
S
h
h
d
d
&
&
f
f
i
i
(
(
l
l
i
i
d
d
i
i
l
l
)
)
d
d
l
l
d
d
t
t
"
a
r
e
c
o
s
s
p
r
o
s
s
n
g
s
c
a
e
o
n
c
o
e
e
o
p
e
p
r
o
g
r
a
m
s
v
-

Management Board

Dr. Simon E. Moroney, CEO

Dr. Moroney is one of MorphoSys's co-founders. He studied chemistry in his native New Zealand, and was a Commonwealth mmonwealth Scholar to the University niversityof Oxford, where he completed mpleteda D. Phil. in 1 D. Phil. in 1984. Subseque Subsequently he was an Associate in the Harvard Medical School, Boston, USA, and an employee of ImmunoGen Inc. Dr. Moroney has held positions at the University of Cambridge, UK, the University of British Columbia, Canada, and the ETH in Zurich, Switzerland. In 2002 he was awarded the German Cross of the Order of Merit by German President Johannes Rau.

Mr Dave Lemus CFOMr. Lemus.

Mr. Lemus joined the Company in 1998, and took MorphoSys public in 1999. Mr. Lemus joined MorphoSys from Roche, where he worked from 1993-1998, and last served as Controller and Operations Manager of 90 pharmaceutical markets. Before this time, he served as Group Treasurer of Lindt & Sprüngli in Zurich, Switzerland, and prior to this, worked in treasury management for Electrolux AB in various countries. Mr. Lemus holds a B.S. degree from the University of Maryland, a M.S. degree from the MIT, and is a Certified Public Accountant (CPA) in the USA.

Dr. Arndt Schottelius, CDO

Dr. Schottelius joined MorphoSys from Genentech Inc., San Francisco, where he served as Medical Director, Immunology Development. Prior to his position at Genentech, Dr. Schottelius held science and management positions in gyp p , gp immunology research at Berlex Biosciences, USA, and Schering , Germany. After medical studies in Germany, UK and Switzerland Dr. Schottelius received his PhD and MD degrees from the Albert-Ludwigs-University, Freiburg, Germany. Subsequently he practiced medicine as a resident physician at the Charité University Hospital, Berlin.

D M li S ll CSODr. Marlies Sproll,

Dr. Marlies Sproll joined MorphoSys in October 2000 as R&D department head. In November 2005, Dr. Sproll was promoted to CSO. Before joining MorphoSys, Dr. Sproll worked for seven years at the Vienna research facility of Boehringer Ingelheim. From 1988 to 1993, Dr. Sproll was lab leader at Merck KGaA in Darmstadt, Germany, where she was involved in the preclinical development of therapeutic antibodies. Dr. Sproll has a Ph.D. from the Max of Planck Institute in Tübingen, Germany, and was awarded a Doctor of Natural Science by the University of Stuttgart.

Sup y ervisoryBoard

Dr. Gerald MöllerChairmanManaging Director of HBM BioVentures, Former President Boehringer-Mannheim

Prof. Dr. Jürgen Drews Vice ChairmanFormer Director Global Research, F.Hoffmann-La Roche

Dr. Walter A. BlättlerFormer Executive Vice President, C O, ect c téde a ce,Former CFO, Aventis , Science and Technology, ImmunoGen

Dr. Daniel CamusCFO, Electricité de France,

Dr. Metin Colpan S i Di t QIAGEN Supervisory Director, Ch i Zi H ldi Li it d Former CEO and Founder, QIAGEN

Dr. Geoffrey Vernon Chairman, Ziggus Holding LimitedFormer Executive Director Rothschild Asset Management

MorphoSys AG – Company Update – April 2009 © MorphoSys AG MorphoSys Page 38

Corporate Calendar 2009

  • April 28, 2009 Q1 2009 Results April 28 2009 28, LBBW German Mid & Small Cap Conference, London, UK May 13, 2009 AGM, Munich
  • May 18 - 19, 2009 Deutsche Bank's 34th Annual Health Care ConferenceBoston, USA
  • May 23-24, 2009 German & Austrian Corporate Conference Frankfurt, Germany
  • June 17 17-18,2009 Jefferies 3rd Annual Healthcare Conference Healthcare New York, USA
  • July 29, 2009 Q2 2009 Results
C
o		 i
v
e
r
n		 A
g		 l
n
a		 t
y
s
s
i
i
I
t
t
t
n
s
o
n
u		 C
t
t
o
n
a
c
B
b
B
k
e
r
e
n
e
r
g
a
n		 M
M
A
A
l
l
d
d
R
R
h
h
s
e
x
a
n
r
a
o
c
e
C
b
k
o
m
m
e
r
z
a
n		 M
D
i
l
W
d
f
f
r.
a
n
e
e
n
o
r
C
d
i
S
i
t
r
e
s
s
e
u		 D
Y
i
A
l-
W
k
l
r.
a
s
r
a
e
e
D
h
B
k
t
e
s
c
e
a
n
u		 M
H
l
B
l
r.
o
g
e
r
m
u
D
Z
B
k
a
n		 D
E
l
K
r.
m
a
r
r
a
s
u
S
E
i
t
I
t
i
t
t
i
l
i
q
u
n
e
n
s
u
o
n
a
e
r
v
c
e
s		 D
M
t
i
P
i
k
r.
a
r
n
o
s
s
e
n
e
L
d
b
k
B
d
W
ü
t
t
b
a
n
e
s
a
n
a
e
n-
r
e
m
e
r
g		 D
H
F
h
r.
a
n
n
s
r
o
n
m
e
y
e
r
S
M
I
D
A
R
h
e
s
e
a
r
c		 S
M
T
h
h
i
l
r.
o
m
a
s
c
e
s
s
e
C
N
d
o
m
u
r
a
o
e		 G
D
W
d
r.
a
r
y
a
a
n
e
r
s
S
l.
O
h
i
a
p
p
e
n
e
m		 D
C
h
i
t
i
P
t
r.
r
s
a
n
e
e
r
S
G
S
i
i
t
e
c
r
e
s
u		 M
R
d
l
h
B
r.
o
p
e
e
s
s
e
r
e
u
v
W
W
L
L
B
B
A
G
t
t
e
s		 D
D
C
C
l
l
i
i
T
T
h
h
r.
o
r
n
e
a
o
m
a
s

Thank You.

www.morphosys.com

Dave Lemus

Chief Financial Officer

Phone +49 (0)89 / 899 27-439 ( ) ( ) Fax +49 (0)89 / 899 27-5439 Email [email protected]

Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email [email protected]

More from MorphoSys AG

AGM Information 2024
Aug 27
Delisting Announcement 2024
Aug 5
AGM Information 2024
Jul 19
AGM Information 2024
Jul 19
Declaration of Voting Results & Voting Rights Announcements 2024
Jul 18
Delisting Announcement 2024
Jul 12
Legal Proceedings Report 2024
Jul 12
Report Publication Announcement 2024
Jul 5
Major Shareholding Notification 2024
Jul 2
Declaration of Voting Results & Voting Rights Announcements 2024
Jun 21
View all filings →